Jefferies raises Nvidia stock price target to $205 on strong demand
David R. Epstein, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold 370 shares of the company’s Class A Common Stock. The shares were sold on February 3, 2025, at an average price of $53.31 each, totaling approximately $19,724. Since then, TEM’s stock has climbed to $69.18, marking a remarkable 105% gain year-to-date for the $9.74 billion market cap company. InvestingPro analysis indicates the stock is currently in overbought territory. Following this transaction, Epstein holds 27,524 shares in the company. The sale was executed under a Rule 10b5-1 trading plan, which Epstein adopted on August 27, 2024. Want deeper insights into TEM’s technical indicators and insider trading patterns? InvestingPro subscribers have access to 12 additional technical and fundamental tips for informed decision-making.
In other recent news, Tempus AI has been making significant strides in the healthcare technology sector. The company recently completed the acquisition of Ambry Genetics, a strategic move that analysts at TD Cowen believe will enhance Tempus AI’s product offerings and expand into new markets. The acquisition brings a profitable germline testing laboratory with over $300 million in revenue to Tempus AI’s portfolio, potentially paving the way for positive free cash flow. TD Cowen has subsequently upgraded Tempus AI’s stock rating and raised the price target to $74.
In addition to this, Tempus AI has launched a personal health concierge app named ’Olivia.’ The app aims to centralize and make actionable the health-related data of patients, marking a significant advancement in precision medicine and patient care through technology. This development is part of Tempus AI’s commitment to improving patient outcomes by leveraging data and AI.
Furthermore, Tempus AI has entered a multi-year agreement with Genialis to validate new RNA-based biomarker algorithms across different cancer types. This collaboration is expected to contribute to the development of more precise and effective cancer treatments. These are all recent developments that showcase Tempus AI’s dedication to innovation in the healthcare technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.